SELENOP and invasive breast carcinoma: The observed prevalence of 7.65% autoimmunity to SELENOP in the patients with primary invasive breast cancer is slightly higher than reported before from patients with autoimmune thyroid disease (6.6%), and healthy subjects (0.3%), respectively.